Certara vs QPS

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/certara/qps

Category	Certara	QPS
Listed site	cro	cro
Summary	Certara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making.	QPS provides integrated contract research and clinical services spanning bioanalysis, preclinical development, and early-to-late phase clinical trials across multiple therapeutic areas including oncology, dermatology, and women's health.
Services	Biostatistics & Statistical Programming Data Management & eClinical Regulatory Affairs Medical Writing Computational & In-Silico Drug Discovery Translational Research Target Identification & Validation High-Throughput Screening Medicinal Chemistry In Vitro Pharmacology In Vitro ADME / DMPK Safety Pharmacology Genetic Toxicology Discovery Research In Vivo Efficacy Models In Vivo PK / PD Studies GLP Toxicology Preclinical In Vitro Studies Preclinical In Vivo Studies Bioanalysis LC-MS Bioanalysis (Small Molecule) Ligand-Binding Bioanalysis (Large Molecule) Phase I Clinical Trials Biomarker Assays Phase II Clinical Trials Phase III Clinical Trials Clinical Operations Phase IV / Post-Marketing US FDA Regulatory Strategy US FDA Regulatory Strategy EU EMA Regulatory Strategy EU EMA Regulatory Strategy Japan PMDA Regulatory Strategy Japan PMDA Regulatory Strategy China NMPA Regulatory Strategy China NMPA Regulatory Strategy Clinical Trial Services	Bioanalysis Flow Cytometry Services Genomics & Sequencing Services Biomarker Assays In Vitro ADME / DMPK In Vitro Pharmacology Preclinical In Vitro Studies In Vivo PK / PD Studies Preclinical In Vivo Studies Safety Pharmacology GLP Toxicology Phase I Clinical Trials Phase II Clinical Trials Phase III Clinical Trials Phase IV / Post-Marketing Clinical Operations Clinical Trial Services Data Management & eClinical Biostatistics & Statistical Programming Medical Writing Pharmacovigilance & Drug Safety Regulatory Affairs US FDA Regulatory Strategy
Modalities	Small Molecule Small Molecule Biologics (Monoclonal Antibodies) Biologics (Monoclonal Antibodies) Biologics (Other) Biologics (Other) Peptide Peptide Oligonucleotide Oligonucleotide mRNA mRNA Antibody-Drug Conjugate (ADC) Antibody-Drug Conjugate (ADC) Gene Therapy Gene Therapy Cell Therapy Cell Therapy Vaccine Vaccine	Small Molecule Biologics (Other) Cell Therapy Gene Therapy Vaccine
Indications	Oncology Rare Disease Immunology Immunology Neurology Neurology Psychiatry Metabolic Metabolic Cardiovascular Cardiovascular Infectious Disease Infectious Disease Respiratory Respiratory Dermatology Dermatology Ophthalmology Ophthalmology Gastroenterology Gastroenterology Nephrology Nephrology Women's Health Women's Health	Oncology Dermatology Women's Health Metabolic Immunology Infectious Disease
Locations	Global network Global presence, 30 countries Global presence, Multiple, 30 countries, Global Global presence, Multiple, 30+ countries Global presence, Multiple, 30 countries, International Headquarters, Radnor, Pennsylvania, United States Global presence, 30 countries Global presence, 30+ countries	Delaware, Delaware, Delaware, USA Miami, Miami, Florida, USA Missouri, Missouri, Missouri, USA The Netherlands, The Netherlands, The Netherlands, Netherlands Austria, Austria, Austria, Austria CTPS, Taiwan, Taiwan, Taiwan NKSP, Taiwan, Taiwan, Taiwan Qualitix, Taiwan, Taiwan, Taiwan India, India, India, India
Certifications	Data not yet provided.	CLIA · Identifier: CLIA
Reviews	Review summary appears after site-level review signal gate opens.	Review summary appears after site-level review signal gate opens.